Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, Massachusetts
- Most recent report
- 8-K, filed Sep 1, 2026
- Incorporated
- Massachusetts
- Filings on record
- 1,001+ filings
- On EDGAR
- CIK 875320
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 25
News 8 of 53
Prospectuses and Registrations 8 of 11
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 POS Post-effective amendment to an employee plan registration May 13, 2026
- S-8 Registration statement for an employee plan May 13, 2026
Proxies 8 of 16
- DEFA14A Extra proxy material Apr 29, 2026
- DEFA14A Extra proxy material Apr 2, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 2, 2026
- DEFA14A Extra proxy material Apr 3, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 3, 2025
- PX14A6G Shareholder's own proxy material Apr 16, 2024
- DEFA14A Extra proxy material Apr 4, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 4, 2024
Ownership 8 of 876
- 4 Insider reported a trade Sep 1, 2026
- 4 Insider reported a trade Aug 31, 2026
- 144 Notice of a proposed sale of restricted stock Aug 27, 2026
- 4 Insider reported a trade Jul 23, 2026
- 4 Insider reported a trade Jul 23, 2026
- 4 Insider reported a trade Jul 17, 2026
- 4 Insider reported a trade Jul 17, 2026
- 4 Insider reported a trade Jul 7, 2026
Other 8 of 20
- UPLOAD Comment letter from SEC staff Apr 14, 2026
- ARS Annual report sent to shareholders Apr 2, 2026
- CORRESP Reply to SEC staff Apr 1, 2026
- UPLOAD Comment letter from SEC staff Mar 18, 2026
- UPLOAD Comment letter from SEC staff May 7, 2025
- CORRESP Reply to SEC staff May 5, 2025
- UPLOAD Comment letter from SEC staff Apr 7, 2025
- ARS Annual report sent to shareholders Apr 3, 2025
What to read: Jun 2026 10-Q
SECSift found 1 of 11 sections worth reading, with 0 positive, 2 notable, and 0 negative flags.
Other Information (Item 5)
Major financing events: $4.5B term loan for Crinetics Acquisition and new $500M revolver.
What changed: Jun 2026 vs. Mar 2026
About 25% of VRTX's Jun 2026 10-Q is new information. 239 paragraphs were added, 176 changed, and 83 removed. Below are the most important lines SECSift identified.
New
- AIPR&D expense rose to $21.4M in Q2 from $0.5M in Q1 due to milestone payments. Item 1
- New $4.5B term loan and $500M revolver entered July 2026. Item 2
- New $500M revolver and $4.5B term loan signed in July 2026, replacing old $500M revolver. Item 1
- Announced $10B acquisition of Crinetics in July 2026. Item 2
- Crinetics acquisition announced July 6, 2026 for ~$10B in cash, to close Q3 2026. Item 1
- Added substantial risk factor specifically for the Crinetics Acquisition and its integration. Item 1A
- Povetacicept PDUFA date assigned Nov 30, 2026. Item 2
Changed
- AIPR&D expenses increased from $0.5M in Q1 2026 to $21.9M in first half 2026. Item 2
- Royalty arbitration adds $0.5B more in cumulative ALYFTREK sales vs Q1; now $1.8B total. Item 1
- Share repurchase authorization remaining decreased from $3.0B to $2.6B. Item 2
- Share repurchase remaining $2.6B vs $3.0B at Q1 2026. Item 1
Removed
Everything here comes from Vertex Pharmaceuticals Inc's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Aug 19, 2026, from the 10-Q for Jun 2026.